LCS
FLXN

Levin Capital Strategies’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Levin Capital Strategies’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-23,000
Closed -$576K – 346
2017
Q4 		$576K Hold
23,000
– – 0.01% 188
2017
Q3 		$556K Buy
+23,000
New +$541K 0.01% 196

Other funds holding FLXN

GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Levin Capital Strategies's FLXN Position: Q1 2018 in Review

Levin Capital Strategies sold out of Flexion Therapeutics, Inc. (FLXN) in Q1 2018, closing a stake of 23,000 shares — an estimated $576K sold.

Levin Capital Strategies first reported a position in FLXN in Q3 2017 and held it in 2 quarters. The position peaked at $576K in Q4 2017. 134 funds tracked by Wall St. Rank hold FLXN as of Q1 2018.

  • Levin Capital Strategies reported no remaining Flexion Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Levin Capital Strategies sold 23,000 Flexion Therapeutics, Inc. shares in Q1 2018, an estimated $576K.
  • Levin Capital Strategies first reported a position in Flexion Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Levin Capital Strategies's Flexion Therapeutics, Inc. position peaked at $576K in Q4 2017.
  • 134 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q1 2018.

Based on Levin Capital Strategies's 13F filing for Q1 2018, filed 18 May 2018.